BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 18505686)

  • 1. A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro.
    Winton MJ; Van Deerlin VM; Kwong LK; Yuan W; Wood EM; Yu CE; Schellenberg GD; Rademakers R; Caselli R; Karydas A; Trojanowski JQ; Miller BL; Lee VM
    FEBS Lett; 2008 Jun; 582(15):2252-6. PubMed ID: 18505686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis.
    Van Deerlin VM; Leverenz JB; Bekris LM; Bird TD; Yuan W; Elman LB; Clay D; Wood EM; Chen-Plotkin AS; Martinez-Lage M; Steinbart E; McCluskey L; Grossman M; Neumann M; Wu IL; Yang WS; Kalb R; Galasko DR; Montine TJ; Trojanowski JQ; Lee VM; Schellenberg GD; Yu CE
    Lancet Neurol; 2008 May; 7(5):409-16. PubMed ID: 18396105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies.
    Igaz LM; Kwong LK; Chen-Plotkin A; Winton MJ; Unger TL; Xu Y; Neumann M; Trojanowski JQ; Lee VM
    J Biol Chem; 2009 Mar; 284(13):8516-24. PubMed ID: 19164285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALS and FTLD: two faces of TDP-43 proteinopathy.
    Liscic RM; Grinberg LT; Zidar J; Gitcho MA; Cairns NJ
    Eur J Neurol; 2008 Aug; 15(8):772-80. PubMed ID: 18684309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developmentally Regulated RNA-binding Protein 1 (Drb1)/RNA-binding Motif Protein 45 (RBM45), a Nuclear-Cytoplasmic Trafficking Protein, Forms TAR DNA-binding Protein 43 (TDP-43)-mediated Cytoplasmic Aggregates.
    Mashiko T; Sakashita E; Kasashima K; Tominaga K; Kuroiwa K; Nozaki Y; Matsuura T; Hamamoto T; Endo H
    J Biol Chem; 2016 Jul; 291(29):14996-5007. PubMed ID: 27226551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation.
    Winton MJ; Igaz LM; Wong MM; Kwong LK; Trojanowski JQ; Lee VM
    J Biol Chem; 2008 May; 283(19):13302-9. PubMed ID: 18305110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional complementation in Drosophila to predict the pathogenicity of TARDBP variants: evidence for a loss-of-function mechanism.
    Vanden Broeck L; Kleinberger G; Chapuis J; Gistelinck M; Amouyel P; Van Broeckhoven C; Lambert JC; Callaerts P; Dermaut B
    Neurobiol Aging; 2015 Feb; 36(2):1121-9. PubMed ID: 25442115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies.
    Cascella R; Capitini C; Fani G; Dobson CM; Cecchi C; Chiti F
    J Biol Chem; 2016 Sep; 291(37):19437-48. PubMed ID: 27445339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [TDP-43 proteinopathies: ALS and frontotemporal dementias].
    Prudlo J
    Fortschr Neurol Psychiatr; 2009 Aug; 77 Suppl 1():S25-7. PubMed ID: 19685386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
    Ito D; Suzuki N
    Neurology; 2011 Oct; 77(17):1636-43. PubMed ID: 21956718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasmic Relocalization of TAR DNA-Binding Protein 43 Is Not Sufficient to Reproduce Cellular Pathologies Associated with ALS
    Wobst HJ; Wesolowski SS; Chadchankar J; Delsing L; Jacobsen S; Mukherjee J; Deeb TZ; Dunlop J; Brandon NJ; Moss SJ
    Front Mol Neurosci; 2017; 10():46. PubMed ID: 28286471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis.
    Rutherford NJ; Zhang YJ; Baker M; Gass JM; Finch NA; Xu YF; Stewart H; Kelley BJ; Kuntz K; Crook RJ; Sreedharan J; Vance C; Sorenson E; Lippa C; Bigio EH; Geschwind DH; Knopman DS; Mitsumoto H; Petersen RC; Cashman NR; Hutton M; Shaw CE; Boylan KB; Boeve B; Graff-Radford NR; Wszolek ZK; Caselli RJ; Dickson DW; Mackenzie IR; Petrucelli L; Rademakers R
    PLoS Genet; 2008 Sep; 4(9):e1000193. PubMed ID: 18802454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death.
    Xiao S; Sanelli T; Chiang H; Sun Y; Chakrabartty A; Keith J; Rogaeva E; Zinman L; Robertson J
    Acta Neuropathol; 2015 Jul; 130(1):49-61. PubMed ID: 25788357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia.
    Mackenzie IR; Rademakers R
    Curr Opin Neurol; 2008 Dec; 21(6):693-700. PubMed ID: 18989115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoplasmic poly-GA aggregates impair nuclear import of TDP-43 in C9orf72 ALS/FTLD.
    Khosravi B; Hartmann H; May S; Möhl C; Ederle H; Michaelsen M; Schludi MH; Dormann D; Edbauer D
    Hum Mol Genet; 2017 Feb; 26(4):790-800. PubMed ID: 28040728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of mutant TAR DNA-binding protein 43 in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.
    Janssens J; Kleinberger G; Wils H; Van Broeckhoven C
    Biochem Soc Trans; 2011 Aug; 39(4):954-9. PubMed ID: 21787329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases.
    Geser F; Martinez-Lage M; Kwong LK; Lee VM; Trojanowski JQ
    J Neurol; 2009 Aug; 256(8):1205-14. PubMed ID: 19271105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Significance of the TDP-43 deposition in FTLD-U and ALS].
    Hasegawa M; Arai T; Nonaka T; Kametani F; Yoshida M; Hashizume Y; Beach TG; Morita M; Nakano I; Oda T; Tsuchiya K; Akiyama H
    Rinsho Shinkeigaku; 2008 Nov; 48(11):994-7. PubMed ID: 19198142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.
    Walker AK; Spiller KJ; Ge G; Zheng A; Xu Y; Zhou M; Tripathy K; Kwong LK; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2015 Nov; 130(5):643-60. PubMed ID: 26197969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis.
    Tan RH; Yang Y; Kim WS; Dobson-Stone C; Kwok JB; Kiernan MC; Halliday GM
    Acta Neuropathol Commun; 2017 Oct; 5(1):76. PubMed ID: 29078806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.